Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Price Target Raised to $122.00

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) had its target price upped by JPMorgan Chase & Co. from $107.00 to $122.00 in a research report sent to investors on Friday morning,Benzinga reports. The firm currently has an overweight rating on the stock.

Several other equities analysts have also recently weighed in on KNSA. Weiss Ratings cut shares of Kiniksa Pharmaceuticals International from a “buy (b-)” rating to a “hold (c-)” rating in a research note on Wednesday. Wedbush lifted their target price on shares of Kiniksa Pharmaceuticals International from $99.00 to $102.00 and gave the company an “outperform” rating in a report on Wednesday, October 28th. Wall Street Zen cut shares of Kiniksa Pharmaceuticals International from a “strong-buy” rating to a “buy” rating in a research note on Sunday, July 12th. Citigroup increased their price objective on Kiniksa Pharmaceuticals International from $60.00 to $100.00 and gave the stock a “buy” rating in a research note on Wednesday, July 29th. Finally, The Goldman Sachs Group boosted their target price on Kiniksa Pharmaceuticals International from $90.00 to $101.00 and gave the stock a “buy” rating in a research report on Wednesday, October 28th. Seven equities research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company. Based on data from MarketBeat, Kiniksa Pharmaceuticals International has a consensus rating of “Moderate Buy” and a consensus price target of $100.57.

Kiniksa Pharmaceuticals International Stock Performance

Shares of KNSA stock opened at $92.24 on Friday. The company’s fifty day moving average price is $79.15 and its 200-day moving average price is $60.03. The stock has a market cap of $7.20 billion, a PE ratio of 70.95 and a beta of 0.07. Kiniksa Pharmaceuticals International has a 12 month low of $36.56 and a 12 month high of $98.48.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) last issued its quarterly earnings results on Tuesday, October 27th. The company reported $0.56 EPS for the quarter, topping analysts’ consensus estimates of $0.37 by $0.19. Kiniksa Pharmaceuticals International had a return on equity of 17.27% and a net margin of 11.58%. The company had revenue of $285.97 million during the quarter, compared to analysts’ expectations of $260.66 million. On average, sell-side analysts forecast that Kiniksa Pharmaceuticals International will post 1.26 earnings per share for the current fiscal year.

Insider Activity

In other Kiniksa Pharmaceuticals International news, CAO Michael Megna sold 4,600 shares of the firm’s stock in a transaction dated Thursday, September 3rd. The stock was sold at an average price of $80.30, for a total transaction of $369,380.00. Following the transaction, the chief accounting officer directly owned 29,062 shares in the company, valued at $2,333,678.60. This trade represents a 13.67% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 51.98% of the stock is owned by insiders.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in the business. Chicago Partners Investment Group LLC purchased a new position in shares of Kiniksa Pharmaceuticals International during the third quarter valued at approximately $226,000. Ascent Group LLC grew its position in Kiniksa Pharmaceuticals International by 16.0% during the third quarter. Ascent Group LLC now owns 3,796 shares of the company’s stock valued at $283,000 after buying an additional 523 shares during the period. Mirae Asset Global Investments Co. Ltd. purchased a new position in shares of Kiniksa Pharmaceuticals International during the third quarter worth $184,000. ProShare Advisors LLC increased its holdings in shares of Kiniksa Pharmaceuticals International by 4.8% in the third quarter. ProShare Advisors LLC now owns 7,408 shares of the company’s stock valued at $553,000 after purchasing an additional 338 shares during the period. Finally, Vise Technologies Inc. grew its position in shares of Kiniksa Pharmaceuticals International by 19.7% in the third quarter. Vise Technologies Inc. now owns 9,177 shares of the company’s stock valued at $685,000 after purchasing an additional 1,512 shares during the period. 53.95% of the stock is owned by institutional investors.

Kiniksa Pharmaceuticals International Company Profile

Kiniksa Pharmaceuticals International plc is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for patients with serious and often under-treated immunological diseases. The company’s research and development efforts are centered on targeting specific pathways involved in inflammation and immune-system dysfunction.

Kiniksa’s principal commercial product is ARCALYST (rilonacept), an interleukin-1 inhibitor. In the United States, ARCALYST is approved for reducing the risk of recurrence in patients with recurrent pericarditis and for the treatment of cryopyrin-associated periodic syndromes, including familial cold autoinflammatory syndrome and Muckle-Wells syndrome, in eligible patients.

The company also maintains a pipeline of investigational medicines designed to address autoimmune and inflammatory conditions.